Precision Biosciences INC Form 4 insider transactions

J. Jefferson Smith, Chief Research Officer of Precision BioSciences, acquired 48,657 restricted stock units on August 22, 2024.

John Alexander Kelly, CFO of Precision BioSciences, reports the acquisition of 79,725 restricted stock units.

Precision BioSciences CEO Michael Amoroso received 208,263 restricted stock units on August 22, 2024, which vest in three equal annual installments starting January 20, 2025.

Dario Scimeca, General Counsel and Secretary of Precision BioSciences, acquired 44,723 restricted stock units on August 22, 2024, which vest annually starting January 20, 2025.

Dario Scimeca, General Counsel and Secretary of Precision BioSciences, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

John Alexander Kelly, CFO of Precision BioSciences, reports the vesting and settlement of Restricted Stock Units (RSUs) on June 7, 2024.

J. Jefferson Smith, Chief Research Officer at Precision BioSciences, reports the vesting of restricted stock units and a sale of shares to cover tax obligations.

Director Melinda Brown acquired 9,826 Restricted Stock Units (RSUs) in Precision BioSciences, Inc. on June 4, 2024, which will vest on the earlier of June 4, 2025, or the day before the next annual meeting.

Director Kevin Buehler acquired 9,826 Restricted Stock Units (RSUs) of Precision BioSciences, Inc. on June 4, 2024, which vest on the earlier of June 4, 2025, or the day before the next annual meeting, contingent upon continued service.

Director Stanley Frankel acquired 9,826 Restricted Stock Units (RSUs) of Precision BioSciences on June 4, 2024.

Director Geno J. Germano acquired 9,826 Restricted Stock Units (RSUs) of Precision BioSciences, Inc. on June 4, 2024, which will vest on the earlier of June 4, 2025, or the day before the next annual meeting, subject to continued service.

Director Shari Lisa Pire acquired 9,826 Restricted Stock Units in Precision BioSciences, vesting on June 4, 2025, or the day before the next annual meeting.

Director Samuel C. Wadsworth acquired 9,826 Restricted Stock Units (RSUs) of Precision BioSciences on June 4, 2024, according to a Form 4 filing.

Michael Amoroso, President and CEO of Precision BioSciences, acquired 8,334 shares of common stock through a private placement at $12 per share.

John Alexander Kelly, CFO of Precision BioSciences, acquired 8,334 shares of common stock through a private placement on May 8, 2024.

J. Jefferson Smith, Chief Research Officer of Precision BioSciences, acquired 833 shares of common stock through a private placement on May 8, 2024.

Dario Scimeca, General Counsel and Secretary of Precision BioSciences, recently purchased additional shares of the company's common stock through a private placement.

Director Shari Lisa Pire reports the vesting and settlement of 4,202 Restricted Stock Units (RSUs) into common stock of Precision BioSciences Inc on May 4, 2024.

Director Kevin Buehler reports the vesting and settlement of Restricted Stock Units (RSUs) into common stock of Precision BioSciences.

Director Samuel C. Wadsworth reports the vesting and settlement of 4,202 Restricted Stock Units into common stock of Precision BioSciences.

Director Geno Germano reports the vesting and settlement of Restricted Stock Units (RSUs) into Precision BioSciences common stock on May 4, 2024.

Director Stanley Frankel reported the vesting and settlement of 4,202 Restricted Stock Units (RSUs) into common stock on May 4, 2024.

Melinda Brown, a director of Precision Biosciences Inc., reported the vesting and settlement of 4,202 Restricted Stock Units (RSUs) on May 4, 2024, resulting in the acquisition of 4,202 shares of common stock.

John Alexander Kelly, CFO of Precision BioSciences, reports the acquisition and disposal of common stock and restricted stock units.

Dario Scimeca, General Counsel and Secretary of Precision BioSciences, sold shares of common stock to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).

J. Jefferson Smith, Chief Research Officer at Precision BioSciences, reports acquisition and disposal of company stock related to RSU vesting and tax obligations.

Alan List, Chief Medical Officer of Precision BioSciences, reports the vesting and sale of common stock to cover tax obligations.

Michael Amoroso, President and CEO of Precision BioSciences, reports the vesting and sale of common stock to cover tax obligations.

Alan List, Chief Medical Officer of Precision BioSciences, reports the vesting and sale of common stock to cover tax obligations.

J. Jefferson Smith, Chief Research Officer of Precision BioSciences, acquired 31,343 restricted stock units on April 18, 2024, according to a Form 4 filing.